There are no data yet to report on this protocol. To date, 40 study subjects have been enrolled as well as 20 controls. 30 study subjects remain actively enrolled at this time (7 lost to death, 2 withdrew due to difficulty traveling back to NIH for exams, and 1 elected to withdraw due to overall burden of medical care). 29 participants have completed at least 1 year of follow-up following autologous stem cell transplant; the final subject will complete 1 year of follow-up in October 2015. A significant portion of the patients have been advised to use topical cyclosporine eye drops in response to changes in ocular indicators (symptoms, drop in Schirmers tear production, or worsening of surface dryness). Our team hopes to correlate changes in patient symptoms and exam findings with changes in the tear fluid biomarkers. We anticipate completing a preliminary data analysis of approximately 30 participants and a control group of 20 by the next reporting period.
|Brooks, Brian P; Thompson, Amy H; Bishop, Rachel J et al. (2013) Ocular manifestations of xeroderma pigmentosum: long-term follow-up highlights the role of DNA repair in protection from sun damage. Ophthalmology 120:1324-36|
|Baird, Kristin; Steinberg, Seth M; Grkovic, Lana et al. (2013) National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. Biol Blood Marrow Transplant 19:632-9|
|Wang, Yujuan; Marciano, Beatriz E; Shen, Defen et al. (2013) Molecular identification of bacterial DNA in the chorioretinal scars of chronic granulomatous disease. J Clin Immunol 33:917-24|
|Smith, Wendy M; Reddy, Madhu G; Hutcheson, Kelly A et al. (2012) Rifabutin-associated hypopyon uveitis and retinal vasculitis with a history of acute myeloid leukemia. J Ophthalmic Inflamm Infect 2:149-52|
|Sibley, Cailin H; Plass, Nikki; Snow, Joseph et al. (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 64:2375-86|